Hervé Hoppenot, Incyte CEO (Credit: Jeff Rumans)

In­cyte changes man­u­fac­tur­ing process, adds sec­ond site to solve Opzelu­ra tex­ture is­sue

From the start of In­cyte’s Q1 earn­ings call, the man­u­fac­tur­ing is­sues sur­round­ing Opzelu­ra were ad­dressed by Hervé Hop­penot, the com­pa­ny’s CEO. And though is­sues have slowed the treat­ment back, the phar­ma said it added a sec­ond man­u­fac­tur­ing site to pro­duce the atopic der­mati­tis drug, and im­ple­ment­ed a new process af­ter gain­ing FDA ap­proval.

“Con­sis­tent with best prac­tices, we have re­ceived FDA ap­proval for a sec­ond man­u­fac­tur­er of Opzelu­ra to sup­port our suc­cess­ful launch,” he said, be­fore hand­ing things over to US gen­er­al man­ag­er Bar­ry Flan­nel­ly. “We are al­so prepar­ing to rein­tro­duce sam­ples in the US.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.